EP0000335A1 - Esters de l'acide N-pyrimidinyl-carboximidique, procédé pour leur préparation et médicaments les contenant. - Google Patents
Esters de l'acide N-pyrimidinyl-carboximidique, procédé pour leur préparation et médicaments les contenant. Download PDFInfo
- Publication number
- EP0000335A1 EP0000335A1 EP78100183A EP78100183A EP0000335A1 EP 0000335 A1 EP0000335 A1 EP 0000335A1 EP 78100183 A EP78100183 A EP 78100183A EP 78100183 A EP78100183 A EP 78100183A EP 0000335 A1 EP0000335 A1 EP 0000335A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pyrimidin
- amino
- ethyl
- trimethoxybenzyl
- sulfanilamido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
Definitions
- the invention relates to new imidates of the formula I. in which R 1 , R 2 and R 3 , which may be the same or different from one another, are hydrogen, methyl, methoxy or chlorine, R 4 is hydrogen or alkyl having 1-4 C atoms, R 5 is alkyl having 1-6 C -Atoms or benzyl, and R 6 is alkyl with 1-4 carbon atoms or benzyl, and n can be 0 or 1.
- the substituents R 1 , R 2 and R 3 are preferably in the 3, 4 and 5 positions of the benzene ring.
- the compounds of formula 1 according to the invention are prepared by the methods customary for the preparation of imidates, as described, inter alia, in Houben-Weyl * Methods of organic chemistry ", Volume 6/3 are described by using a compound of formula II wherein R 1 , R 2 , R 3 , R 4 and n have the meaning given above, with an orthocarboxylic acid ester of the formula III in which R 5 and R 6 have the meaning given above.
- the compounds of the formula I can be prepared with or without a solvent, the latter being carried out with an excess of the orthocarboxylic acid ester used.
- suitable solvents are dimethylformamide or dioxane.
- the reaction temperatures are between 0 and 150 o C, preferably between 50 and 100 ° C or at temperatures up to the boiling point of the solvent or orthocarboxylic acid ester used.
- the reaction can optionally be carried out in the presence of catalytic amounts of an acid, such as hydrochloric acid.
- the compounds of the formula I according to the invention are antimicrobially active in diseases caused by bacteria and protozoa and, combined with sulfonamides, potentiate their antimicrobial activity. They can therefore be used, for example, for bacterial diseases of the respiratory, digestive and urinary tract, as well as for throat, nose and ear infections and general systemic infectious diseases and malaria.
- the compounds of the formula I can be combined with the sulfonamides mentioned by way of example in various mixing ratios, the ratio of the compound of the formula I to sulfonamide being able to vary from 1:10 to 5: 1. Preferred mixing ratios are 1: 1 to 1: 5. As a rule, 20 to 500 mg of an active ingredient of the formula I are suitable as doses.
- the present invention accordingly also relates to chemotherapeutic agents which, in addition to conventional carriers and diluents, contain a compound of the formula I, in particular in combination with a sulfonamide, as active ingredients, and the use of the compounds of the formula I as sulfonamide potentiators.
- chemotherapeutic agents or preparations are produced in a known manner with the usual carriers or diluents and the commonly used pharmaceutical-technical auxiliaries in accordance with the desired type of application.
- the preferred preparations are in a dosage form which is suitable for oral administration.
- Dosage forms of this type are, for example, tablets, film-coated tablets, dragees, capsules, pills, powders, solutions or suspensions.
- the active ingredients are mixed with corn starch and granulated with an aqueous gelatin solution.
- the dry granulate is sieved and mixed with the aggregates. Tablets are pressed from this mixture in the usual way.
- the active ingredients are granulated with an aqueous gelatin solution and, after drying, mixed with corn starch, talc and magnesium stearate. Tablets are pressed from this mixture in the usual way.
- the active ingredients are mixed with corn starch and granulated with an aqueous gelatin solution.
- the dry granulate is sieved and mixed with the aggregates. Tablets are pressed from this mixture in the usual way.
- the finely ground active ingredients are suspended in the aqueous tylose mucus. Then all other ingredients are added in succession with stirring. Finally, make up to 100.0 g with water.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19772730468 DE2730468A1 (de) | 1977-07-06 | 1977-07-06 | Neue n-pyrimidinyl-imidsaeureester, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
DE2730468 | 1977-07-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000335A1 true EP0000335A1 (fr) | 1979-01-24 |
EP0000335B1 EP0000335B1 (fr) | 1981-10-07 |
Family
ID=6013253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78100183A Expired EP0000335B1 (fr) | 1977-07-06 | 1978-06-19 | Esters de l'acide N-pyrimidinyl-carboximidique, procédé pour leur préparation et médicaments les contenant. |
Country Status (15)
Country | Link |
---|---|
US (1) | US4315931A (fr) |
EP (1) | EP0000335B1 (fr) |
JP (1) | JPS5416483A (fr) |
AR (1) | AR220139A1 (fr) |
AT (1) | AT360998B (fr) |
AU (1) | AU515679B2 (fr) |
CA (1) | CA1107733A (fr) |
DE (2) | DE2730468A1 (fr) |
DK (1) | DK142577C (fr) |
FI (1) | FI782174A (fr) |
HU (1) | HU178177B (fr) |
IE (1) | IE47013B1 (fr) |
IL (1) | IL55020A (fr) |
NO (1) | NO782341L (fr) |
ZA (1) | ZA783874B (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3045720A1 (de) * | 1980-12-04 | 1982-07-08 | Basf Ag, 6700 Ludwigshafen | N-pyrimidinyl-carbaminsaeureester, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
US4767443A (en) * | 1984-09-20 | 1988-08-30 | Ciba-Geigy Corporation | Antifungal and antibacterial diazine derivatives compositions, intermediates, and method of use therefor |
CH668969A5 (de) * | 1986-09-05 | 1989-02-15 | Ciba Geigy Ag | Verfahren zur bekaempfung unerwuenschten pflanzenwuchses sowie zur regulierung des pflanzenwachstums. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3049544A (en) * | 1962-08-14 | Method for the preparation of | ||
DE2732029A1 (de) * | 1977-07-15 | 1979-02-01 | Basf Ag | Neue amidino-benzylpyrimidine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
-
1977
- 1977-07-06 DE DE19772730468 patent/DE2730468A1/de not_active Withdrawn
-
1978
- 1978-06-05 FI FI782174A patent/FI782174A/fi not_active Application Discontinuation
- 1978-06-19 EP EP78100183A patent/EP0000335B1/fr not_active Expired
- 1978-06-19 DE DE7878100183T patent/DE2861128D1/de not_active Expired
- 1978-06-27 IL IL55020A patent/IL55020A/xx unknown
- 1978-06-28 IE IE1292/78A patent/IE47013B1/en unknown
- 1978-06-30 AU AU37643/78A patent/AU515679B2/en not_active Expired
- 1978-07-03 US US06/921,701 patent/US4315931A/en not_active Expired - Lifetime
- 1978-07-04 AR AR272832A patent/AR220139A1/es active
- 1978-07-04 HU HU78BA3671A patent/HU178177B/hu unknown
- 1978-07-05 NO NO782341A patent/NO782341L/no unknown
- 1978-07-05 CA CA306,847A patent/CA1107733A/fr not_active Expired
- 1978-07-05 DK DK303278A patent/DK142577C/da active
- 1978-07-05 ZA ZA00783874A patent/ZA783874B/xx unknown
- 1978-07-05 AT AT487678A patent/AT360998B/de not_active IP Right Cessation
- 1978-07-06 JP JP8153178A patent/JPS5416483A/ja active Pending
Non-Patent Citations (1)
Title |
---|
Keine Entgegenhaltungen. * |
Also Published As
Publication number | Publication date |
---|---|
IL55020A0 (en) | 1978-08-31 |
US4315931A (en) | 1982-02-16 |
IE781292L (en) | 1979-01-06 |
ATA487678A (de) | 1980-07-15 |
DE2730468A1 (de) | 1979-01-18 |
AR220139A1 (es) | 1980-10-15 |
CA1107733A (fr) | 1981-08-25 |
HU178177B (en) | 1982-03-28 |
FI782174A (fi) | 1979-01-07 |
EP0000335B1 (fr) | 1981-10-07 |
ZA783874B (en) | 1979-08-29 |
DE2861128D1 (en) | 1981-12-17 |
NO782341L (no) | 1979-01-09 |
DK142577B (da) | 1980-11-24 |
JPS5416483A (en) | 1979-02-07 |
DK303278A (da) | 1979-01-07 |
IL55020A (en) | 1981-11-30 |
DK142577C (da) | 1981-07-20 |
AU3764378A (en) | 1980-01-03 |
AT360998B (de) | 1981-02-10 |
AU515679B2 (en) | 1981-04-16 |
IE47013B1 (en) | 1983-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH637385A5 (de) | Verfahren zur herstellung von pyrimidin-derivaten und von deren pharmakologisch vertraeglichen salzen. | |
CH645352A5 (en) | N-Lower alkyl-3-phenoxy-1-azetidinecarboxamides | |
DE3446371C2 (fr) | ||
DE2204574A1 (de) | Verfahren zur herstellung von 3-aminobenzo-1,2,4-triazin-di-n-oxiden (1,4) | |
EP1581506B1 (fr) | Utilisation de derives de 2-amino-2h-quinazoline pour la preparation de produits therapeutiques | |
DE69623760T2 (de) | Kaliumionen-kanal-blocker | |
AT391864B (de) | Verfahren zur herstellung von neuen 5-pyrimidincarboxamiden und deren additionssalzen | |
EP0000334B1 (fr) | 2,4-Diamino-5-benzylpyrimidines, procédé pour leur préparation et médicaments les contenant | |
DE2052719A1 (de) | Verfahren zur Herstellung von neuen 5 Nitrofuryldenvaten | |
DE3216843C2 (de) | 3-Thiomethyl-pyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
EP0000335B1 (fr) | Esters de l'acide N-pyrimidinyl-carboximidique, procédé pour leur préparation et médicaments les contenant. | |
DE3035688C2 (fr) | ||
EP0132811A1 (fr) | Hydroxyméthyl-4 pyrrolidinones substituées en position 1, procédés pour leur préparation, compositions pharmaceutiques et produits intermédiaires | |
EP0000336B1 (fr) | N-benzylpyrimidinyl-amidines, procédé pour leur préparation et médicaments les contenant | |
DE2833986A1 (de) | Immunstimulierende n-substituierte aziridin-2-carbonsaeurederivate, verfahren zu ihrer herstellung sowie arzneimittel, die diese substanzen enthalten | |
EP0053695A2 (fr) | Esters de l'acide N-pyrimidinylcarbamique, leur procédé de préparation et médicaments les contenant | |
DE3217325A1 (de) | 3-amino-6-aryl-1,2,4-triazolo(4,3-b)-pyridazine, ihre herstellung und ihre verwendung | |
CH634566A5 (de) | Benzylpyrimidine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. | |
EP0097297B1 (fr) | 5-Phénylthio-6-amino-pyrimidinones substituées, leur procédé de préparation et leur usage, de même que les préparations contenant ces composés | |
EP0049538A2 (fr) | Utilisation des dérivés de thiourée comme médicaments dans le traitement des dérèglements du métabolisme des lipides | |
DE2319281A1 (de) | Diuretisches und antihypertensives mittel | |
EP0253182A1 (fr) | Utilisation de thiadiazinones pour combattre les endoparasites | |
DE2823715A1 (de) | 4-amino-2-dichloracetamido-5-(3,4,5- trimethoxybenzyl)-pyrimidin, verfahren zu seiner herstellung und diese verbindung enthaltende arzneimittel | |
DE2439283A1 (de) | Neue pyrimidinderivate und verfahren zu deren herstellung | |
AT360041B (de) | Verfahren zur herstellung von neuen 9-substi- tuierten 2-aminopurinen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
17P | Request for examination filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
REF | Corresponds to: |
Ref document number: 2861128 Country of ref document: DE Date of ref document: 19811217 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19820525 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19820630 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19820630 Year of fee payment: 5 Ref country code: NL Payment date: 19820630 Year of fee payment: 5 Ref country code: DE Payment date: 19820630 Year of fee payment: 5 Ref country code: CH Payment date: 19820630 Year of fee payment: 5 Ref country code: BE Payment date: 19820630 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19820705 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19830429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19830619 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19830620 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19830630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19840101 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19840229 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881117 |
|
EUG | Se: european patent has lapsed |
Ref document number: 78100183.9 Effective date: 19850610 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |